Sativex Versus Placebo When Added to Existing Treatment for Central Neuropathic Pain in MS
A Double Blind, Randomised, Placebo Controlled, Parallel Group Study of Sativex When Added to the Existing Treatment Regimen, in the Relief of Central Neuropathic Pain in Subjects With Multiple Sclerosis
Sponsor: GW Pharmaceuticals Ltd
Listed as NCT00391079, this PHASE3 trial focuses on Multiple Sclerosis and remains completed. Sponsored by GW Pharmaceuticals Ltd, it has been updated 8 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE3
-
Mar 2022 — Dec 2022 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
Jan 2021 — Mar 2022 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Sep 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GW Pharmaceuticals Ltd
For direct contact, visit the study record on ClinicalTrials.gov .